DD264924A5 - Verfahren zur herstellung von pyrimidin-nucleosiden - Google Patents

Verfahren zur herstellung von pyrimidin-nucleosiden Download PDF

Info

Publication number
DD264924A5
DD264924A5 DD87310427A DD31042787A DD264924A5 DD 264924 A5 DD264924 A5 DD 264924A5 DD 87310427 A DD87310427 A DD 87310427A DD 31042787 A DD31042787 A DD 31042787A DD 264924 A5 DD264924 A5 DD 264924A5
Authority
DD
German Democratic Republic
Prior art keywords
group
compound
hydrogen
formula
hydroxy
Prior art date
Application number
DD87310427A
Other languages
German (de)
English (en)
Inventor
Saad G Rahim
Dorothy J M Purifoy
Original Assignee
��������@��������@����������@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ��������@��������@����������@���k�� filed Critical ��������@��������@����������@���k��
Publication of DD264924A5 publication Critical patent/DD264924A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
  • Developing Agents For Electrophotography (AREA)
DD87310427A 1986-12-15 1987-12-14 Verfahren zur herstellung von pyrimidin-nucleosiden DD264924A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds

Publications (1)

Publication Number Publication Date
DD264924A5 true DD264924A5 (de) 1989-02-15

Family

ID=10609013

Family Applications (2)

Application Number Title Priority Date Filing Date
DD87310427A DD264924A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung von pyrimidin-nucleosiden
DD87320503A DD274766A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung einer pharmazeutischen formulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DD87320503A DD274766A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung einer pharmazeutischen formulierung

Country Status (30)

Country Link
US (1) US5079235A (ja)
EP (3) EP0486477A3 (ja)
JP (2) JPS63165397A (ja)
KR (1) KR880007521A (ja)
CN (2) CN87108265A (ja)
AT (1) ATE88713T1 (ja)
AU (2) AU601529B2 (ja)
CA (1) CA1319143C (ja)
CS (3) CS275402B6 (ja)
DD (2) DD264924A5 (ja)
DE (1) DE3785651T2 (ja)
DK (2) DK654287A (ja)
ES (1) ES2054693T3 (ja)
FI (2) FI875487A (ja)
GB (1) GB8629892D0 (ja)
HU (4) HU207735B (ja)
IE (2) IE930470L (ja)
IL (3) IL95141A (ja)
LT (1) LT2064B (ja)
LV (1) LV5273A3 (ja)
MC (1) MC1882A1 (ja)
MX (1) MX9203216A (ja)
NO (1) NO167576C (ja)
NZ (1) NZ222898A (ja)
PH (2) PH24104A (ja)
PL (3) PL158050B1 (ja)
PT (1) PT86356B (ja)
RU (1) RU2036199C1 (ja)
SU (1) SU1731064A3 (ja)
ZA (1) ZA879382B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851889T2 (de) * 1987-06-24 1995-04-13 Florey Howard Inst Nukleosid-derivate.
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
JP3094036B2 (ja) * 1990-07-19 2000-10-03 ザ ウエルカム ファウンデーション リミテッド 酵素不活性化剤
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
EP1256589A3 (en) * 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
CA2118405A1 (en) * 1992-05-26 1993-09-12 Robert Maurice Ippolito Immunosuppressive and tolerogenic modified lewisc and lacnac compounds
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
RU98113785A (ru) * 1995-12-22 2000-06-10 Ист Каролина Юниверсити (US) Агент и способ лечения заболеваний, связанных с чрезмерной экспрессией цитидиндезаминазы или дезоксицитидинзаминазы
WO1997027849A1 (fr) * 1996-02-02 1997-08-07 Showa Shell Sekiyu K.K. Medicaments pour traiter les infections provoquees par le virus de l'herpes et compositions preventives pour empecher un retour de l'infection, contenant tous les deux des derives triterpeniques comme principe actif
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
JP4651942B2 (ja) 2001-12-20 2011-03-16 フアーマセツト・インコーポレイテッド Ｅｂｖ及びｋｈｓｖ感染並びにそれに伴う異常細胞増殖の治療
US8318756B2 (en) 2004-12-03 2012-11-27 Adherex Technologies, Inc. Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
SI2757091T1 (en) 2008-04-01 2018-01-31 Biosearch Technologies, Inc. Stabilized nucleic acid black gas-fluorofor probe
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
WO2011047195A1 (en) 2009-10-14 2011-04-21 Adherex Technologies, Inc. Treating neurotoxicity associated with combinations of 5 - fu or its prodrugs and dpd inhibitors
ES2764226T3 (es) * 2014-03-30 2020-06-02 Cepheid Oligómeros polinucleotídicos de citosina modificados y métodos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
CN87108265A (zh) 1988-07-13
ES2054693T3 (es) 1994-08-16
JPH0378370B2 (ja) 1991-12-13
IL84810A (en) 1992-05-25
DE3785651D1 (de) 1993-06-03
NZ222898A (en) 1990-12-21
IL95141A0 (en) 1991-06-10
CA1319143C (en) 1993-06-15
AU626041B2 (en) 1992-07-23
PT86356A (en) 1988-01-01
KR880007521A (ko) 1988-08-27
CS275398B2 (en) 1992-02-19
EP0417560A1 (en) 1991-03-20
PL160322B1 (pl) 1993-02-26
DE3785651T2 (de) 1993-11-11
DK169991A (da) 1991-10-04
MC1882A1 (fr) 1989-01-24
CS767588A3 (en) 1991-02-12
JPH03141292A (ja) 1991-06-17
FI941523A (fi) 1994-03-31
HU903829D0 (en) 1990-11-28
EP0272065A2 (en) 1988-06-22
IL95141A (en) 1992-05-25
AU8252187A (en) 1988-06-16
HU202112B (en) 1991-02-28
SU1731064A3 (ru) 1992-04-30
FI941523A0 (fi) 1994-03-31
NO875209D0 (no) 1987-12-14
CS275402B6 (en) 1992-02-19
HU199867B (en) 1990-03-28
EP0486477A3 (en) 1992-06-17
PH24104A (en) 1990-03-05
MX9203216A (es) 1992-07-01
DK169991D0 (da) 1991-10-04
ZA879382B (en) 1989-08-30
FI875487A (fi) 1988-06-16
DD274766A5 (de) 1990-01-03
NO167576C (no) 1991-11-20
ATE88713T1 (de) 1993-05-15
AU5989090A (en) 1990-11-08
US5079235A (en) 1992-01-07
NO875209L (no) 1988-06-16
JPS63165397A (ja) 1988-07-08
HUT46336A (en) 1988-10-28
DK654287A (da) 1988-06-16
PL277927A1 (en) 1989-08-21
PT86356B (pt) 1990-11-07
NO167576B (no) 1991-08-12
PL269462A1 (en) 1989-06-26
DK654287D0 (da) 1987-12-14
EP0272065A3 (en) 1988-11-17
GB8629892D0 (en) 1987-01-28
PL160321B1 (pl) 1993-02-26
IE930470L (en) 1988-06-15
PL277926A1 (en) 1989-08-21
HU200932B (en) 1990-09-28
FI875487A0 (fi) 1987-12-14
LV5273A3 (lv) 1993-10-10
CN1080292A (zh) 1994-01-05
DK168323B1 (da) 1994-03-14
EP0272065B1 (en) 1993-04-28
PL158050B1 (pl) 1992-07-31
PH24870A (en) 1990-12-26
IE930471L (en) 1988-06-15
CS916187A2 (en) 1991-02-12
LT2064B (lt) 1993-06-15
RU2036199C1 (ru) 1995-05-27
AU601529B2 (en) 1990-09-13
IL84810A0 (en) 1988-06-30
HU207735B (en) 1993-05-28
EP0486477A2 (en) 1992-05-20
CS342591A3 (en) 1992-04-15

Similar Documents

Publication Publication Date Title
DD264924A5 (de) Verfahren zur herstellung von pyrimidin-nucleosiden
DD282229A5 (de) Verfahren zur herstellung von therapeutischen acyclischen nucleosiden
EP0682027B1 (de) Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
AT390000B (de) Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten
DE69729887T2 (de) Purin-L-Nukleoside, Analoga und deren Verwendung
DD282694A5 (de) Antivirale verbindungen
DE3204596C2 (ja)
DE2539963A1 (de) Purinverbindungen und ihre salze, sowie verfahren zu ihrer herstellung
DD284679A5 (de) Verfahren zur herstellung von adenosin 5'-carboamidderivate
CH676712A5 (ja)
US4863906A (en) 2'-deoxy-5-ethynyluridine-3',5'-diestens for treatment of VZV and CMV infections
EP0023594A1 (de) Trans-Chinazolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte und Arzneimittel enthaltend solche Chinazolinderivate
DE69821758T2 (de) Hemisulfat eines carbocyclischen nucleosides und seine verwendung zur behandlung von viralen infektionen
DE3228060A1 (de) Verfahren zum behandeln von wuchernden hautkrankheiten
EP0374096A1 (de) 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
CH629807A5 (de) Verfahren zur herstellung neuer substituierter purine.
DD289534A5 (de) Verfahren zur herstellung von antiviralen verbindungen
DD251984A5 (de) Verfahren zur herstellung von 3'-azidonucleosiden und pharmazeutisch vertraeglichen derivaten davon
US5028596A (en) 1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections
DE2708827C2 (ja)
CH646958A5 (de) 6-aryl- und 6-heteroaryl-pyrimidin-derivate.
DD270656A5 (de) Verfahren zur herstellung eines aeusserlich anwendbaren, antiviralen, in der haut akkumulierenden pharmazeutischen praeparates
DE4021006A1 (de) Pyrimidin-derivate, deren herstellung und verwendung sowie diese enthaltende arzneimittel
CH658653A5 (de) Verfahren zur herstellung von pyrimidintrionderivaten.
EP0095641A1 (de) Chinazolinonderivate, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee